Healthcare Global Enterprises (HCG)₹588.35−1.92%Hospital
In the Jun 2026 quarter (consolidated), Healthcare Global Enterprises reported sales of ₹693 Cr, up 13.3% from Jun 2025, and net profit of ₹16.02 Cr, up 166.6% year on year. For the year to Mar 2026, sales were ₹2,538 Cr and net profit ₹23.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 486 | 469 | 493 | 525 | 552 | 558 | 584 | 612 | 646 | 632 | 650 | 693 |
| Expenses | 401 | 390 | 402 | 434 | 450 | 469 | 478 | 504 | 523 | 523 | 525 | 571 |
| Operating Profit | 85.23 | 79.27 | 92.32 | 91.34 | 102 | 88.28 | 106 | 108 | 123 | 110 | 125 | 122 |
| OPM % | 17.0% | 16.9% | 18.9% | 17.0% | 18.0% | 16.0% | 18.0% | 17.9% | 18.9% | 16.9% | 18.9% | 17.9% |
| Other Income | 2.99 | 5.98 | 8.97 | 8.97 | 10.96 | 5.98 | 9.96 | 7.97 | 2.99 | −9.97 | −17.95 | 12.96 |
| Interest | 26.93 | 28.96 | 26.96 | 33.92 | 35.93 | 40.92 | 43.93 | 44.93 | 43.92 | 44.93 | 42.95 | 39.96 |
| Depreciation | 43.09 | 44.08 | 46.07 | 47.07 | 50.08 | 57.09 | 58.12 | 58.10 | 63.09 | 61.08 | 63.12 | 70.09 |
| Profit before tax | 18.04 | 11.01 | 28.03 | 19.03 | 28.06 | −3.01 | 14.03 | 12.02 | 20.05 | −6.01 | 1.01 | 25.03 |
| Tax % | 40.0% | 69.0% | 17.0% | 28.0% | 25.0% | −335.0% | 50.0% | 50.0% | −4.0% | 30.0% | −223.0% | 34.0% |
| Exceptional items | 0.00 | 0.00 | 2.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −7.97 | −31.86 | 0.00 |
| Net Profit | 11.01 | 3.01 | 23.01 | 14.02 | 21.01 | 8.01 | 7.01 | 6.01 | 21.01 | −8.01 | 4.01 | 16.02 |
| EPS (Rs) | 0.91 | 0.38 | 1.43 | 0.81 | 1.21 | 0.46 | 0.49 | 0.31 | 1.08 | −0.62 | 0.14 | 0.91 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 583 | 698 | 827 | 974 | 1,090 | 1,006 | 1,391 | 1,687 | 1,902 | 2,213 | 2,538 | 2,621 |
| Expenses | 497 | 594 | 710 | 861 | 933 | 884 | 1,157 | 1,391 | 1,576 | 1,828 | 2,073 | 2,142 |
| Operating Profit | 85.26 | 105 | 116 | 112 | 158 | 122 | 235 | 298 | 328 | 385 | 468 | 481 |
| OPM % | 14.9% | 14.9% | 13.9% | 10.9% | 13.9% | 11.9% | 17.0% | 18.0% | 16.9% | 17.0% | 17.9% | 18.4% |
| Other Income | −1.99 | 9.97 | 24.91 | 9.97 | 9.97 | −71.72 | 110 | 14.95 | 23.93 | 38.85 | −17.95 | −11.97 |
| Interest | 37.95 | 22.96 | 41.90 | 69.87 | 138 | 119 | 97.79 | 104 | 109 | 155 | 177 | 172 |
| Depreciation | 44.07 | 57.16 | 71.19 | 85.19 | 148 | 159 | 158 | 163 | 174 | 211 | 244 | 257 |
| Profit before tax | 0.00 | 35.05 | 27.04 | −33.08 | −119 | −230 | 88.14 | 45.06 | 68.08 | 57.12 | 27.03 | 40.08 |
| Tax % | −730.1% | 34.0% | 38.0% | −7.0% | 5.0% | −3.0% | 56.0% | 61.0% | 39.0% | 14.0% | 15.0% | — |
| Exceptional items | −2.53 | 1.46 | 5.41 | −0.07 | 0.06 | −91.23 | 44.93 | −0.51 | 1.04 | −0.52 | −24.71 | −39.83 |
| Net Profit | 2.01 | 23.01 | 17.01 | −30.99 | −125 | −221 | 38.99 | 18.01 | 41.01 | 49.01 | 23.01 | 33.03 |
| EPS (Rs) | −0.15 | 2.43 | 2.22 | −2.65 | −11.32 | −14.52 | 3.64 | 1.98 | 3.26 | 3.00 | 0.91 | 1.51 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 69.84 | 84.89 | 85.95 | 86.89 | 87.90 | 88.93 | 125 | 139 | 139 | 139 | 139 | 149 |
| Reserves | 209 | 340 | 346 | 427 | 388 | 292 | 571 | 729 | 719 | 684 | 781 | 1,180 |
| Borrowings | 348 | 323 | 419 | 463 | 656 | 1,343 | 974 | 913 | 897 | 1,270 | 1,832 | 1,730 |
| Other Liabilities | 146 | 293 | 370 | 459 | 513 | 516 | 355 | 431 | 546 | 598 | 776 | 851 |
| Total Liabilities | 773 | 1,040 | 1,221 | 1,435 | 1,645 | 2,239 | 2,025 | 2,212 | 2,302 | 2,692 | 3,529 | 3,911 |
| Fixed Assets | 526 | 581 | 683 | 825 | 966 | 1,640 | 1,378 | 1,543 | 1,547 | 1,752 | 2,434 | 2,455 |
| CWIP | 41.89 | 121 | 148 | 174 | 153 | 45.88 | 29.94 | 21.94 | 17.96 | 82.80 | 24.93 | 18.96 |
| Investments | 0.00 | 64.21 | 11.03 | 53.15 | 49.12 | 34.11 | 26.08 | 9.02 | 10.03 | 10.03 | 11.02 | 14.03 |
| Other Assets | 204 | 274 | 380 | 384 | 477 | 519 | 592 | 639 | 727 | 847 | 1,059 | 1,423 |
| Inventories | 15.06 | 13.04 | 19.07 | 24.11 | 27.09 | 23.10 | 21.09 | 30.13 | 38.16 | 43.14 | 53.23 | 60.24 |
| Trade receivables | 63.75 | 69.67 | 103 | 128 | 156 | 185 | 186 | 216 | 302 | 293 | 399 | 419 |
| Cash & equivalents | 27.06 | 58.13 | 85.20 | 29.06 | 21.02 | 32.05 | 41.07 | 198 | 197 | 303 | 349 | 542 |
| Total Assets | 773 | 1,040 | 1,221 | 1,435 | 1,645 | 2,239 | 2,025 | 2,212 | 2,302 | 2,692 | 3,529 | 3,911 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 60.07 | 73.12 | 91.17 | 98.10 | 98.18 | 130 | 121 | 220 | 253 | 285 | 317 | 348 |
| Cash from investing activity | −79.09 | −204 | −211 | −283 | −238 | −101 | −171 | 125 | −133 | −226 | −489 | −177 |
| Cash from financing activity | 22.05 | 217 | 89.22 | 161 | 84.19 | −58.18 | 112 | −155 | −140 | −64.14 | −42.08 | 242 |
| Net cash flow | 1.99 | 84.86 | −28.95 | −23.95 | −55.91 | −29.98 | 61.91 | 190 | −21.98 | −4.99 | −213 | 409 |
| Capex | 79.89 | 210 | 192 | 256 | 189 | 108 | 34.95 | 70.86 | 133 | 186 | 209 | 291 |
| Free cash flow | −19.99 | −137 | −101 | −158 | −90.01 | 23.01 | 84.94 | 150 | 126 | 101 | 110 | 58.99 |
| CFO / OP % | 87.1% | 99.0% | 93.1% | 88.1% | 121.1% | 100.1% | 68.1% | 104.1% | 92.0% | 101.1% | 91.1% | 81.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 45 | 43 | 54 | 57 | 59 | 62 | 67 | 57 | 65 | 56 | 66 | 60 |
| Inventory days | 36 | 32 | 40 | 46 | 45 | 35 | 32 | 31 | 33 | 33 | 33 | 32 |
| Days payable | 209 | 265 | 273 | 275 | 304 | 235 | 222 | 200 | 215 | 217 | 211 | 186 |
| Cash conversion cycle | −127 | −188 | −178 | −171 | −200 | −136 | −121 | −112 | −116 | −127 | −111 | −93 |
| Working capital days | −64 | −95 | −111 | −73 | −109 | −101 | −25 | −42 | −39 | −69 | −90 | −60 |
| ROCE % | 7.0% | 6.0% | 7.0% | 6.0% | 3.0% | 1.0% | −1.0% | 5.0% | 8.0% | 9.1% | 9.1% | 8.0% |
For the Jun 2026 quarter, Healthcare Global Enterprises reported sales of ₹693 Cr, up 13.3% year on year and net profit of ₹16.02 Cr, up 166.6% year on year. The operating margin was 17.9%.
Healthcare Global Enterprises' sales for the year to Mar 2026 were ₹2,538 Cr; over the last twelve months they were ₹2,621 Cr.
Net profit for the year to Mar 2026 was ₹23.01 Cr, and ₹33.03 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.51.
Healthcare Global Enterprises reported borrowings of ₹1,730 Cr at Mar 2026, against cash and equivalents of ₹542 Cr.
Cash from operations was ₹348 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹58.99 Cr.